US researchers have revealed(link is external) the identity of molecules on the surface of cancer cells which allow the body’s immune system to identify and destroy them.
The research could lead to a new generation of immunotherapies that are far more effective than those currently in use, that could target a range of cancers.
“This is a huge breakthrough,” said Cancer Research UK’s Dr Sergio Quezada, who works at UCL in London and was not involved in the research.
“The researchers were looking for ‘signatures’ on the surface of cancer cells associated with response to current immunotherapies, but their findings go further than that. They’ve actually discovered molecular motifs that will inform the development of the next generation of therapies,” he added.
The researchers, led by a team at the Memorial Sloan Kettering Cancer Centre in New York, analysed cancer DNA from 64 melanoma patients who had been treated with an immunotherapy drug called ipilimumab, half of whom had responded to the drug.
Ipilimumab works by switching on the body’s immune system to attack their cancer, but – for unknown reasons – it only works effectively in a minority of patients.
“We’ve been using a drug that empirically was found to be quite effective, and yet we didn’t have a detailed understanding of how it was working in people,” said Memorial Sloan Kettering’s Dr Jedd Wolchok.
Having analysed the patients’ cancer DNA, the researchers used sophisticated software to look for genetic mutations in the cancer cells that could predict whether patients had, or hadn’t, responded to the drug.
In doing so, they uncovered a series of genetic mutations in some of the patients that caused the cancer cells to produce short stretches of protein molecules, called peptide antigens, that make cancerous cells visible to immune response.
Tantalisingly, it appears that these mutations cause the antigens to mimic small parts of proteins produced by bacteria and viruses, explaining why they are so effective at triggering the immune response – although the researchers say more research will be needed to confirm this.
The discovery is “big, big news” for immunotherapy researchers says Cancer Research UK’s Dr Quezada. “This is the first time we’ve had an idea of what the immune system actually ‘sees’ on a tumour. Until now, it’s been hot topic of debate,” he said.
The Latest on: Immunotherapies
via Google News
The Latest on: Immunotherapies
- CytomX Lands $80M to Kick Off Cancer Drug R&D Pact With Astellason March 24, 2020 at 8:42 am
CytomX Therapeutics is teaming up with Astellas Pharma in a research and development alliance focused on developing new cancer immunotherapies based on its antibody technology. Under deal terms ...
- eTheRNA Launches an International Consortium and Starts Development of Cross-strain Protective CoV-2 mRNA Vaccine for High Risk Populationson March 24, 2020 at 1:09 am
eTheRNA Immunotherapies nv ('eTheRNA' or 'The Company'), a clinical-stage company developing vaccines and immunotherapies from its proprietary mRNA TriMix platform, today announced that a consortium h ...
- Primmune Therapeutics Raises USD 7 Million Seed Financing to Develop Novel Oral TLR7 Immunotherapies for Cancer and Acute Viral Diseaseson March 18, 2020 at 11:36 pm
SAN DIEGO: Primmune Therapeutics announced that it has raised USD 7 million in seed financing to support the development of novel orally-administered, small molecule toll-like receptor 7 (TLR7) ...
- Immatics Announces Business Combination with Arya Sciences Acquisition Corp., Creating a Publicly Listed Leader in TCR-based Immunotherapieson March 17, 2020 at 6:17 am
HOUSTON, Texas & TUEBINGEN, Germany--(BUSINESS WIRE)--Immatics Biotechnologies GmbH (“Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of ...
- Immatics Announces Business Combination with Arya Sciences Acquisition Corp., Creating a Publicly Listed Leader in TCR-based Immunotherapieson March 17, 2020 at 5:35 am
Immatics' expertise in identifying cancer targets and developing the right TCRs for immunotherapies, provided exactly that opportunity for this investment vehicle. We look forward to working ...
- Immatics Announces Business Combination with Arya Sciences Acquisition Corp., Creating a Publicly Listed Leader in TCR-based Immunotherapieson March 17, 2020 at 5:30 am
Immatics Biotechnologies GmbH ("Immatics" or the "Company"), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, today ...
- Cancer Immunotherapies Market By Current Industry Status,Growth Opportunities, Top Key Players, Target Audience And Forecast To 2026on March 12, 2020 at 2:44 am
A recent report provides crucial insights along with application based and forecast information in the Global Cancer Immunotherapies Market. The report provides a comprehensive analysis of key factors ...
- Scientists uncover a mechanism that could lead to new immunotherapies head and neck canceron March 10, 2020 at 8:18 am
Researchers at UC have discovered a previously unknown mechanism that could explain the reason behind decreased immune function in cancer patients and could be a new therapeutic target for ...
- Primmune Therapeutics Raises $7 Million Seed Financing to Develop Novel Oral TLR7 Immunotherapies for Cancer and Acute Viral Diseaseson March 2, 2020 at 5:10 am
Primmune Therapeutics is harnessing the power of the innate immune system to develop small molecule, orally administered toll-like receptor 7 (TLR7) agonists as immunotherapies for the treatment ...
- Primmune Therapeutics Raises $7 Million Seed Financing to Develop Novel Oral TLR7 Immunotherapies for Cancer and Acute Viral Diseaseson March 2, 2020 at 12:00 am
agonists as immunotherapies for the treatment of cancer and viral diseases. For more information, please visit: www.primmunerx.com. SHARE THIS POST your MARKET VIEW Find News ...
via Bing News